Selective GLP-1 receptor agonist
GLP-1 (SG)
Selective GLP-1 receptor agonist, the most-researched compound class in metabolic recalibration.
- Half-life~7 days
- Dose range0.25 mg/wk → titrate to 2.4 mg/wk over 16 weeks
- Reconstituted stability28 days, 2–8 °C
- VerificationCOA included
Mechanism
How it works.
Binds GLP-1 receptor; slows gastric emptying, increases satiety, improves insulin sensitivity. Acts on hypothalamic appetite circuits.
Research
What the research shows.
Phase 3 clinical trials in non-diabetic populations show 12–17% body-weight reduction at 68 weeks vs. placebo. GI side effects (nausea, constipation) are common in the titration phase and resolve as the body adapts.
A selective glucagon-like peptide-1 receptor agonist. Binds the GLP-1 receptor in the pancreas, gut, and CNS to slow gastric emptying, blunt appetite signaling, and improve insulin sensitivity.
Run on a once-weekly schedule with a 12–16 week titration period from a starting dose to the target maintenance dose.
Contraindications
When not to use.
Personal/family history of medullary thyroid carcinoma or MEN-2 syndrome. Active pancreatitis. Pregnancy.
Optimal pairings
Stacks well with.
Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.